Jilin Province Deshang Pharmaceutical Co., Ltd.

Main purpose of study: According to the relevant provisions of bioequivalence test, Olmesartan medoxomil orodisintegrating tablets (trade name: Olmetec: specification: 20mg) of Daiichi Sankyo Pharmaceutical Co., Ltd. was selected as the reference preparation, and the test preparation Olmesartan medoxomil orodisintegrating tablets (specification: 20mg) produced by Jilin Deshang Pharmaceutical Co., Ltd. was conducted on the fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation Olmesartan medoxomil orodisintegrating tablets (specification: 20mg) and the reference preparation Olmesartan medoxomil orodisintegrating tablets (trade name: Olmetec: specification: 20mg) by healthy volunteers.

According to the relevant provisions of bioequivalence tests, the reference preparation was selected as Ezetimibe Atorvastatin Calcium Tablets (trade name: Atozet®, specification: 10mg/10mg) produced by Organon Healthcare GmbH, and the test preparation Ezetimibe Atorvastatin Calcium Tablets (specification: 10mg/10mg) produced by Jilin Deshang Pharmaceutical Co., Ltd. and provided by Beijing Mange Pharmaceutical Technology Co., Ltd. was used for fasting and postprandial human bioequivalence preliminary test to evaluate the pharmacokinetic characteristics of the two preparations and provide a reference for the formal test design. At the same time, the safety of healthy subjects after oral administration of the test preparation and the reference preparation was observed.

The main purpose of the study: According to the relevant provisions of the bioequivalence test, ABBOTT LABORATORIES (M) SDN. BHD was selected as the reference preparation, and the test preparation succinate succinate enteric-coated tablets (specification: 0.5g) produced and provided by Jilin Deshang Pharmaceutical Co., Ltd. was used for the preliminary human bioequivalence test after meal administration, and the pharmacokinetic characteristics of the test preparation and the reference preparation after meal administration were estimated, so as to provide a certain reference basis for the design of the formal test. The secondary purpose of the study: To observe the safety of the test preparation succinate succinate enteric-coated tablets (specification: 0.5g) and the reference preparation succinate succinate enteric-coated tablets (trade name: Transmetil, specification: 0.5g) taken orally by healthy volunteers.